Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Petrie

Showing results (501-510 of 557) with videos related to

Pageof 56
Sort By:
JACC. Heart Failure|February 7, 2021
Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HFLi Shen, Søren Lund Kristensen, Olof Bengtsson, et al.
Journal of the American College of Cardiology|September 1, 2024
Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related Heart FailureScott D Solomon, John W Ostrominski, Xiaowen Wang, et al.
JACC. Heart Failure|June 27, 2024
2-Year Outcomes of an Atrial Shunt Device in HFpEF/HFmrEF: Results From REDUCE LAP-HF IIFinn Gustafsson, Mark C Petrie, Jan Komtebedde, et al.
Journal of the American College of Cardiology|November 22, 2023
Semaglutide in Patients With Obesity and Heart Failure Across Mildly Reduced or Preserved Ejection FractionJaved Butler, Steen Z Abildstrøm, Barry A Borlaug, et al.
Lancet (London, England)|November 8, 2022
Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trialPaul R Kalra, John G F Cleland, Mark C Petrie, et al.
ESC Heart Failure|September 15, 2025
Empagliflozin after myocardial infarction with or without diabetes and chronic kidney disease: Insights from EMPACT-MIFrancesco Fioretti, Javed Butler, Jacob A Udell, et al.
ESC Heart Failure|September 19, 2025
SGLT2 inhibitors for the prevention and treatment of heart failure: A scientific statement of the HFA and the HFAIMarco Metra, Daniela Tomasoni, Marianna Adamo, et al.
European Journal of Heart Failure|April 29, 2025
The efficacy of finerenone on hierarchical composite endpoint analysed using win statistics in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of FINEARTS-HFToru Kondo, Pardeep S Jhund, Alasdair D Henderson, et al.
JAMA Cardiology|May 21, 2025
Finerenone in Heart Failure With Improved Ejection Fraction: The FINEARTS-HF Randomized Clinical TrialMaria A Pabon, Orly Vardeny, Muthiah Vaduganathan, et al.
JAMA Cardiology|October 25, 2023
Viability and Outcomes With Revascularization or Medical Therapy in Ischemic Ventricular Dysfunction: A Prespecified Secondary Analysis of the REVIVED-BCIS2 TrialDivaka Perera, Matthew Ryan, Holly P Morgan, et al.
Pageof 56

Showing results (501-510 of 557) with videos related to

Sort By:
Pageof 56
JACC. Heart Failure|February 7, 2021
Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HFLi Shen, Søren Lund Kristensen, Olof Bengtsson, et al.
Journal of the American College of Cardiology|September 1, 2024
Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related Heart FailureScott D Solomon, John W Ostrominski, Xiaowen Wang, et al.
JACC. Heart Failure|June 27, 2024
2-Year Outcomes of an Atrial Shunt Device in HFpEF/HFmrEF: Results From REDUCE LAP-HF IIFinn Gustafsson, Mark C Petrie, Jan Komtebedde, et al.
Journal of the American College of Cardiology|November 22, 2023
Semaglutide in Patients With Obesity and Heart Failure Across Mildly Reduced or Preserved Ejection FractionJaved Butler, Steen Z Abildstrøm, Barry A Borlaug, et al.
Lancet (London, England)|November 8, 2022
Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trialPaul R Kalra, John G F Cleland, Mark C Petrie, et al.
ESC Heart Failure|September 15, 2025
Empagliflozin after myocardial infarction with or without diabetes and chronic kidney disease: Insights from EMPACT-MIFrancesco Fioretti, Javed Butler, Jacob A Udell, et al.
ESC Heart Failure|September 19, 2025
SGLT2 inhibitors for the prevention and treatment of heart failure: A scientific statement of the HFA and the HFAIMarco Metra, Daniela Tomasoni, Marianna Adamo, et al.
European Journal of Heart Failure|April 29, 2025
The efficacy of finerenone on hierarchical composite endpoint analysed using win statistics in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of FINEARTS-HFToru Kondo, Pardeep S Jhund, Alasdair D Henderson, et al.
JAMA Cardiology|May 21, 2025
Finerenone in Heart Failure With Improved Ejection Fraction: The FINEARTS-HF Randomized Clinical TrialMaria A Pabon, Orly Vardeny, Muthiah Vaduganathan, et al.
JAMA Cardiology|October 25, 2023
Viability and Outcomes With Revascularization or Medical Therapy in Ischemic Ventricular Dysfunction: A Prespecified Secondary Analysis of the REVIVED-BCIS2 TrialDivaka Perera, Matthew Ryan, Holly P Morgan, et al.
Pageof 56